the total amount paid out in life claims was £129.4m, with £13.46m paid in terminal illness claims.
.
"we were quite surprised to find there were no significant differences," says study author
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.: "fremanezumab for the preventive treatment of chronic migraine."
.
pdf
.